LungLifeAI™

12 October 2021

LungLife AI, Inc.
(the "**Company**" or "**LungLife**")

PLA Code application submitted in first step in reimbursement process

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical Association.

Reimbursement in the US is comprised of three components: code, price, and coverage. The code is the mechanism by which clinical laboratories can more specifically identify their tests when billing Medicare and commercial insurers. If LungLife's application for a PLA code is granted, the code will be priced for Medicare by the Centers for Medicare & Medicaid Services (CMS) in 2022. PLA code applications can be made at four times in the year.

For further information please contact:

LungLife AI, Inc.	**www.lunglifeai.com**
Paul Pagano, CEO	**Via Walbrook PR**
David Anderson, CFO	
Investec Bank plc (Nominated Adviser & Broker)	**Tel: +44 (0)20 7597 5970**
Daniel Adams / Virginia Bull / Cameron MacRitchie	
Walbrook PR Limited	**Tel: +44 (0)20 7933 8780** or **LungLifeAI@walbrookpr.com**
Paul McManus / Alice Woodings	Mob: 07980 541 893 / 07407 804 654